The continuing unethical conduct of underpowered clinical trials

JAMA

Volumn 288, Issue 3, 2002, Pages 358-362

  Halpern, Scott D ^a   Karlawish, Jason H T ^a   Berlin, Jesse A ^a  

^a Center for Clinical Epidemiology and Biostatistics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DEVICE; DRUG SCREENING; ETHICS; HUMAN; INFORMED CONSENT; META ANALYSIS; PLANNING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 0037125417     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.3.358     Document Type: Article

References (46)

1. Type II errors and ethics
2. Statistics and ethics in medical research III: How large a sample?
3. The ethical design of human experiments
4. Scientific value and validity as ethical requirements for research: A proposed explication
5. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: Survey of 71 "negative" trials
6. Statistical power, sample size, and their reporting in randomized controlled trials
7. Reporting on methods in clinical trials
8. Statistical problems in the reporting of clinical trials
9. Randomization and baseline comparisons in clinical trials
10. Clinical trials in general surgical journals: Are methods better reported?
11. A critical evaluation of the methodology of the literature on medication compliance
12. Sample size and statistical power in clinical orthopaedic research
13. Size and quality of randomised controlled trials in head injury: Review of published studies
14. What makes clinical research ethical?
15. Meta-analytic stimulus for changes in clinical trials
16. Why "underpowered" trials are not necessarily unethical
17. The overemphasis on power analysis
18. Defining the clinically important difference in pain outcome measures
19. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect"
20. Prospective meta-analysis of cholesterol-lowering studies: The Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration
21. The promise and problems of meta-analysis
22. Publication bias: A problem in interpreting medical data
23. Meta-analysis: Bias in location and selection of studies
24. Small clinical trials: Are they all bad?
25. Time to register randomised trials
26. Attitudes toward clinical trials among patients and the public
27. Participation in a clinical trial: The patients' point of view
28. Clinical trial participant satisfaction: Survey of SHEP enrollees
29. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States
30. What patients say about medical research
31. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study
32. How do Alzheimer's disease patients and their caregivers decide whether to enroll in a clinical trial?
33. The scandal of poor medical research
34. The ethics of sample size: Two-sided testing and one-sided thinking
35. Recruitment experience in clinical trials: Literature summary and annotated bibliography
36. Patient recruitment and enrollment
37. Physicians' reasons for not entering eligible patients in a randomized clinical trial of adjuvant surgery for breast cancer
38. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
39. Who will enroll? predicting participation in a phase II AIDS vaccine trial
40. Suspended judgement: AIDS and the ethics of clinical trials: Learning the right lessons
41. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results
42. The role of meta-analysis in the regulatory process for foods, drugs, and devices